Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Novel adoptive cell therapies for acute lymphoblastic leukaemia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.05.19
Views: 406

Prof Rupert Handgretinger, Director and Chair, Children’s University Hospital and Department of Haematology/Oncology, Tübingen, Germany

Prof Rupert Handgretinger talks to ecancer at the European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia about the various novel therapies that are being developed to treat acute lymphoblastic leukaemia (ALL).

He describes the use of allogeneic haploidentical stem cell transplantation as an immunotherapy to treat children with acute lymphoblastic leukaemia (ALL).

Given the positive initial outcomes achieved, Prof Handgretinger mentions that the next step will be to carry out a prospective, multi-centre clinical trial in patients with advanced leukaemia.

He also mentions the use of memory natural killer (NK) cells and CAR T cells as a post-transplant adoptive T cell therapy.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content. 

Related videos

follow us

Tobacco Dependence e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation